Editing Anandamide (section)

===Obesity and liver disease===
Blockade of CB1 receptors was found to improve lipid resistance and lipid profile in obese subjects with [[type 2 diabetes]].<ref>{{cite journal | vauthors = Gruden G, Barutta F, Kunos G, Pacher P | title = Role of the endocannabinoid system in diabetes and diabetic complications | journal = British Journal of Pharmacology | volume = 173 | issue = 7 | pages = 1116–1127 | date = April 2016 | pmid = 26076890 | pmc = 4941127 | doi = 10.1111/bph.13226 }}</ref> Elevated anandamide levels are found in people with [[nonalcoholic fatty liver disease]], [[nonalcoholic steatohepatitis]], and [[liver fibrosis]].<ref>{{cite journal | vauthors = Kimberly WT, O'Sullivan JF, Nath AK, Keyes M, Shi X, Larson MG, Yang Q, Long MT, Vasan R, Peterson RT, Wang TJ, Corey KE, Gerszten RE | title = Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis | journal = JCI Insight | volume = 2 | issue = 9 | pages = e92989 | date = May 2017 | pmid = 28469090 | pmc = 5414569 | doi = 10.1172/jci.insight.92989 }}</ref>